Provenance
Written by SPS and the College of Sexual and Reproductive Health (CoSRH), with the support of specialist stakeholders working within clinical practice, for use within reproductive services.
August 2025 – note the Faculty of Sexual and Reproductive Healthcare (FSRH) has now changed its name to the College of Sexual and Reproductive Healthcare (CoSRH). Some web pages and CoSRH documents will continue to display the FSRH name; where you see FSRH, this refers to CoSRH. All weblinks are still active. The wording in the PGD/protocol templates will be updated at their next review.
Template versions available
Version 3.0 of this PGD template, valid from April 2026, has been published to allow organisations to undertake local governance processes in a timely manner.
Version 2.3 of this PGD template remains currently valid and will be removed from this page on its expiry (31st March 2026)
PGD template attachment
The template PGD is attached below to download and use in conjunction with our implementation advice.
More reproductive health PGD templates
- Combined hormonal contraceptive vaginal ring
- Levonorgestrel 1500 microgram tablets for emergency contraception
- Ulipristal acetate 30mg tablets for emergency contraception
- Combined oral hormonal contraceptive (COC) in reproductive health
- Combined hormonal contraceptive transdermal patch
- Copper Intrauterine Device (Cu-IUD)
- Lidocaine 10mg/ml spray for IUC insertion or removal
- Lidocaine plus prilocaine cream for IUC insertion or removal
- Progestogen-Only Intra-Uterine Device (LNG-IUD) for contraception
- Medroxyprogesterone acetate (SC-DMPA) injection for contraception
- Medroxyprogesterone acetate (DMPA) IM injection for contraception
- Etonogestrel (e.g. Nexplanon®) implant for contraception
- Lidocaine injection for subdermal etonogestrel in contraception
All PGD templates
National PGD templates
Update history
- Republished
- Version 3 published and explanatory wording added. Page reviewed
- Information added regarding name change of FSRH to CoSRH
- Version 2.3 published. Added statement to reflect new FSRH advice on desogestrel and risk of meningioma. Updated references.
- Detail of planned update added following new FSRH advice
- Details of a planned update to this template added
- Updated template published (changes detailed within document)
- Updated template published
- Title, URL and summary amended.
- Version 1 removed as expiring end March '23
- Version 2.0 PGD template added
- Published